Echo Therapeutics Regains Compliance with Nasdaq Listing Requirements

    Echo Therapeutics Regains Compliance with Nasdaq Listing Requirements

PR Newswire

PHILADELPHIA, June 26, 2013

PHILADELPHIA, June 26, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq:
ECTE), a company developing its needle-free Symphony^® CGM System as a
non-invasive, wireless continuous glucose monitoring system, today announced
that it has been notified by the Nasdaq Stock Market ("Nasdaq") that the
Company has regained compliance with the $1.00 minimum bid price requirement
for continued listing on the Nasdaq Capital Market.

(Logo: http://photos.prnewswire.com/prnh/20120801/NE50071LOGO )

As previously disclosed, on March 19, 2013, the Nasdaq Listing Qualifications
department notified the Company that its common stock failed to maintain a
minimum bid price of $1.00 over the previous 30 consecutive business days and,
as a result, the Company was not in compliance with Listing Rule 5550(a)(2).
The company was provided 180 calendar days, or until September 16, 2013, to
regain compliance.

On June 25, 2013, Nasdaq notified the Company that the closing bid price of
its common stock has been at $1.00 per share or greater for the last 12
consecutive business days. Accordingly, Nasdaq confirmed that the Company has
regained compliance with the minimum bid price rule and that the matter is now
closed.

"We are very pleased to have regained compliance with the Nasdaq listing
requirements. We remain focused on increasing shareholder value by executing
on several key clinical and regulatory milestones this year to bring the
Symphony CGM System to market," commented Patrick T. Mooney, M.D., Chairman
and CEO of Echo Therapeutics.

About Echo Therapeutics

Echo Therapeutics is developing the Symphony CGM System as a non-invasive,
wireless continuous glucose monitoring system. Our target is patients who
could benefit from glucose monitoring in the hospital setting, including
critical care. Significant opportunity also exists for patients with diabetes
to use Symphony in the outpatient setting. Echo is also developing its
needle-free skin preparation component of Symphony, the Prelude^® SkinPrep
System, as a platform technology to enhance drug delivery of topical
pharmaceuticals.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may
constitute forward-looking statements including, without limitation, the
statement regarding our plan to execute on several key clinical and regulatory
milestones this year, that are based on current expectations and are subject
to risks and uncertainties that could cause actual future results to differ
materially from those expressed or implied by such statements. Those risks and
uncertainties include, but are not limited to, risks related to regulatory
approvals and the success of Echo's ongoing studies, including the safety and
efficacy of Echo's Symphony CGM System, the failure of future development and
preliminary marketing efforts related to Echo's Symphony CGM System, Echo's
ability to secure additional commercial partnering arrangements, risks and
uncertainties relating to Echo's and its partners' ability to develop, market
and sell the Symphony CGM System, the availability of substantial additional
equity or debt capital to support its research, development and product
commercialization activities, and the success of its research, development,
regulatory approval, marketing and distribution plans and strategies,
including those plans and strategies related to its Symphony CGM System. These
and other risks and uncertainties are identified and described in more detail
in Echo's filings with the Securities and Exchange Commission, including,
without limitation, its Annual Report on Form 10-K for the year ended December
31, 2012, its Quarterly Reports on Form 10-Q, and its Current Reports on Form
8-K. Echo undertakes no obligation to publicly update or revise any
forward-looking statements.

For More Information:

Christine H. Olimpio
Director, Investor Relations and Corporate Communications
(215) 717-4104

Connect With Us:

- Visit our website at www.echotx.com
- Follow us on Twitter at www.twitter.com/echotx
- Join us on Facebook at www.facebook.com/echotx



SOURCE Echo Therapeutics, Inc.

Website: http://www.sontra.com